DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Cervical
Cancer – Market Insights, Epidemiology and Market Forecast – 2023 –
United States” drug pipelines to their offering.
The global market size of prophylaxis treatment for Cervical Cancer is
expected to grow at a CAGR of 0.71% and reach up to USD 2210.9 Million
This report provides marketed drugs information of Cervical Cancer. It
includes historical and forecasted epidemiology and market size of the
Cervical Cancer of US for 2013 – 2023. It is estimated that the market
size of Cervical Cancer in United States is expected to grow at a
Compound Annual Growth Rate of 0.68% and reach up to USD 96.28 million
Cervical Cancer needs to be focused more and more because it adversely
affects younger women. It is the fourth most common cause of death among
women. Cervical Cancer occurs due to the uncontrolled growth of healthy
cells in cervix and forms cervical lesions. It spreads to other tissues
such as vagina and uterus. Cervical Cancer is caused by inheritance of
defects or mutation in genes.
– Report covers the disease overview including pathophysiology,
symptoms, diagnosis, disease management, and current treatment options.
– Marketed information including available prescription drugs, its
patent and exclusivity details.
– The Report also covers the detailed global historical and forecasted
epidemiological data for United States from 2013 – 2023.
– It also provides Market size of Cervical Cancer for United States from
2013 and forecasted Market size to 2023.
– The report will help in developing business strategies by
understanding the trends shaping and driving the United States market
size of the Cervical Cancer.
– Identifying patient populations in the United States Cervical Cancer
market to improve product design, pricing, and launch plans.
– To understand the future market competition in United States Cervical
Cancer therapeutics market, as well as prophylaxis and Insightful review
of the key market drivers and barriers.
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/lhbc29/cervical_cancer
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716